Reversion of P-Glycoprotein-Mediated Multidrug Resistance in Human Leukemic Cell Line by Diallyl Trisulfide

Figure 2

Concentration of adriamycin in K562 or K562/A02 cells.

(a) K562 cells

(b) K562/A02 cells

(c) K562 cells + ADM (adriamycin)

(d) K562/A02 cells + ADM (adriamycin)

(e) K562/A02 cells + DATS + ADM (adriamycin)

(f) K562/A02 cells + VRP (verapamil) + ADM (adriamycin)

(g) K562/A02 cells were treated with DATS (2 μmol/L) or verapamil (4 mg/L) for 48 h, then adriamycin (5 mg/L) was added and coincubated for a further 2 h